Literature DB >> 27496472

Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.

M Grąt1, K M Wronka2, M Krasnodębski2, Ł Masior2, Z Lewandowski3, I Kosińska4, K Grąt5, J Stypułkowski2, S Rejowski2, M Wasilewicz2, M Gałęcka6, P Szachta6, M Krawczyk2.   

Abstract

BACKGROUND: Changes within the gut microbiota contribute to the progression of chronic liver diseases. According to the results of several studies performed in animal models, gut dysbiosis plays an important role in hepatocarcinogenesis. The aim of this study was to explore the characteristics of gut microbiota associated with the presence of hepatocellular cancer (HCC) in patients with cirrhosis of the liver undergoing liver transplantation.
METHODS: A total of 15 patients with HCC and 15 non-HCC patients matched according to etiology of cirrhosis and Model for End-Stage Liver Disease (MELD) scores who underwent liver transplantations between 2012 and 2014 were included. Analysis of their gut microbial profile was based on prospectively collected stool samples from the pretransplant period.
RESULTS: Patients with and without HCC were similar with respect to age (P = .506), sex (P = .700), hepatitis C virus (P > .999) and hepatitis B virus (P = .715) infection status, alcoholic liver disease (P > .999), and MELD score (P = .337). Notably, the presence of HCC was associated with significantly increased fecal counts of Escherichia coli (P = .025). Prediction of HCC presence based on E coli counts was associated with the area under the receiver-operating curve of 0.742 (95% confidence interval, 0.564-0.920), with the optimal cutoff on the level of 17.728 (natural logarithm of colony-forming units per 1 g of feces). Sensitivity and specificity rates for the established cutoff were 66.7% and 73.3%, respectively.
CONCLUSIONS: The profile of gut microbiota associated with the presence of HCC in cirrhotic patients is characterized by increased fecal counts of E coli. Therefore, intestinal overgrowth of E coli may contribute to the process of hepatocarcinogenesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27496472     DOI: 10.1016/j.transproceed.2016.01.077

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  50 in total

Review 1.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

Review 4.  The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Authors:  Marco Sanduzzi Zamparelli; Alba Rocco; Debora Compare; Gerardo Nardone
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

5.  Improve gut microbiome: a new horizon of cancer therapy.

Authors:  Hiroshi Fukui
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

6.  Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?

Authors:  M Olmedo; E Reigadas; M Valerio; S Vázquez-Cuesta; J A Pajares; A Matilla; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2019-03-08       Impact factor: 1.553

Review 7.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

8.  Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer.

Authors:  Vishal Singh; Beng San Yeoh; Benoit Chassaing; Xia Xiao; Piu Saha; Rodrigo Aguilera Olvera; John D Lapek; Limin Zhang; Wei-Bei Wang; Sijie Hao; Michael D Flythe; David J Gonzalez; Patrice D Cani; Jose R Conejo-Garcia; Na Xiong; Mary J Kennett; Bina Joe; Andrew D Patterson; Andrew T Gewirtz; Matam Vijay-Kumar
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

Review 9.  Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians.

Authors:  Celeste Allaband; Daniel McDonald; Yoshiki Vázquez-Baeza; Jeremiah J Minich; Anupriya Tripathi; David A Brenner; Rohit Loomba; Larry Smarr; William J Sandborn; Bernd Schnabl; Pieter Dorrestein; Amir Zarrinpar; Rob Knight
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-18       Impact factor: 11.382

Review 10.  The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction.

Authors:  Kosuke Mima; Keisuke Kosumi; Yoshifumi Baba; Tsuyoshi Hamada; Hideo Baba; Shuji Ogino
Journal:  Hum Genet       Date:  2020-11-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.